Results 161 to 170 of about 51,507 (268)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source

Pharmacophoric Investigation of a Natural Product-like Class of Aromatase Inhibitors Using Molecular Modeling. [PDF]

ACS Omega
Held A, Esselman A, Huebner M, Frietas G, Boyson B, Walker M, Miller B.   +6 more
europepmc   +1 more source

Aromatase inhibitors.

Journal of Synthetic Organic Chemistry, Japan, 1988
openaire   +2 more sources

Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension

British Journal of Pharmacology, Volume 183, Issue 9, Page 1824-1844, May 2026.
Background and Purpose The contribution of obesity to pulmonary arterial hypertension (PAH) pathophysiology remains poorly understood. Adipose tissue synthesises estrogens via cytochrome P450 (CYP) 19A1 (aromatase), whereas circulating estrogens are metabolised in the lung by CYP1A1.
Joshua P. Dignam, Smriti Sharma, Gregor Aitchison, Ayman Gebril, Ioannis Stasinopoulos, Sofia Laforest, Chelbi Coyle, Ruth Andrew, Natalie Z. M. Homer, Sébastien Bonnet, Sandra Breuils‐Bonnet, Martin Wabitsch, Margaret R. MacLean   +12 more
wiley   +1 more source

Cardiovascular Risks of Aromatase Inhibitors versus Tamoxifen in Postmenopausal Breast Cancer: A Multinational Cohort Study. [PDF]

Clin Epidemiol
Hu SC, Gaber CE, Lo C, Su HN, Wang CC, Yeh CF, Hassan L, Pickard AS, Lee TA, Lin FJ.   +9 more
europepmc   +1 more source

Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain

British Journal of Pharmacology, Volume 183, Issue 9, Page 2009-2027, May 2026.
Abstract Background and Purpose Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might ...
Maria Fernanda Pessano Fialho, Raquel Tonello, Evelyne Silva Brum, Gabriela Becker, Nigel W. Bunnett, Sara Marchesan Oliveira   +5 more
wiley   +1 more source

Exploring the Impact of In Ovo Injection of Flavonoid-Based Aromatase Inhibitors on Gonadal Histology Differentiation in Ross 308 Broiler Chickens. [PDF]

Vet Med Sci
Akbari-Balajorshari A, Mottaghitalab M, Hossein-Zadeh NG, Mohammadghasemi F.   +3 more
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Letter to the Editor "Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer". [PDF]

Breast
Verma A, Hoysal DR, Deshpande A, Badwe RA.   +3 more
europepmc   +1 more source

Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Osteoporosis is a prevalent skeletal disorder characterised by progressive reduction in bone mass, microarchitectural deterioration, and increased fracture susceptibility. In India, approximately one‐third of the elderly population is affected by bone‐related disorders, and the global burden of osteoporosis continues to rise.
Pramoda G., Kamini Shivhare, Piyush Kumar Gupta, Amirhossein Sahebkar, Prashant Kesharwani, Rahul Shukla   +5 more
wiley   +1 more source